JP2015518819A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518819A5
JP2015518819A5 JP2015511675A JP2015511675A JP2015518819A5 JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5 JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5
Authority
JP
Japan
Prior art keywords
viral protein
protein complex
animal
viral
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/040228 external-priority patent/WO2013169961A1/en
Publication of JP2015518819A publication Critical patent/JP2015518819A/ja
Publication of JP2015518819A5 publication Critical patent/JP2015518819A5/ja
Pending legal-status Critical Current

Links

JP2015511675A 2012-05-09 2013-05-09 立体構造的に特異的なウイルス免疫原 Pending JP2015518819A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644830P 2012-05-09 2012-05-09
US61/644,830 2012-05-09
PCT/US2013/040228 WO2013169961A1 (en) 2012-05-09 2013-05-09 Conformationally specific viral immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018088600A Division JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原

Publications (2)

Publication Number Publication Date
JP2015518819A JP2015518819A (ja) 2015-07-06
JP2015518819A5 true JP2015518819A5 (https=) 2016-06-30

Family

ID=49548782

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015511675A Pending JP2015518819A (ja) 2012-05-09 2013-05-09 立体構造的に特異的なウイルス免疫原
JP2018088600A Expired - Fee Related JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原
JP2020073065A Pending JP2020125323A (ja) 2012-05-09 2020-04-15 立体構造的に特異的なウイルス免疫原
JP2022128985A Active JP7472209B2 (ja) 2012-05-09 2022-08-12 立体構造的に特異的なウイルス免疫原

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018088600A Expired - Fee Related JP6692853B2 (ja) 2012-05-09 2018-05-02 立体構造的に特異的なウイルス免疫原
JP2020073065A Pending JP2020125323A (ja) 2012-05-09 2020-04-15 立体構造的に特異的なウイルス免疫原
JP2022128985A Active JP7472209B2 (ja) 2012-05-09 2022-08-12 立体構造的に特異的なウイルス免疫原

Country Status (7)

Country Link
US (6) US20130302366A1 (https=)
EP (2) EP2846828B1 (https=)
JP (4) JP2015518819A (https=)
AU (5) AU2013259548A1 (https=)
CA (1) CA2873048C (https=)
IN (1) IN2014DN09445A (https=)
WO (1) WO2013169961A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013551A1 (en) * 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
US9393297B2 (en) 2013-08-03 2016-07-19 Avatar Medical, Llc Influenza hemagglutinin proteins and methods of use thereof
WO2019032480A1 (en) 2017-08-07 2019-02-14 Avatar Medical, Llc PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
AU2021271016A1 (en) * 2020-05-12 2023-01-19 The Regents Of The University Of California SARS-CoV2 neutralizing single domain antibody constructs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
DE60043708D1 (de) * 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
CA2387870C (en) 1999-10-15 2012-02-14 Avatar Medical, Llc Stabilized proteins
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
EP1463521A4 (en) 2001-12-17 2009-06-24 Us Gov Health & Human Serv INHIBITOR OF GP41
WO2004069863A2 (en) 2003-02-04 2004-08-19 New York University Constrained hiv v3 loop peptides as immunogens and receptor antagonists
JP5009614B2 (ja) * 2003-07-03 2012-08-22 アバター バイオテクノロジーズ，インク． 免疫原性を低減した分子の取得方法
EP1755667B1 (en) * 2004-06-01 2013-07-17 Merck Sharp & Dohme Corp. Stable peptide mimetic of hiv gp41 fusion intermediate
CA2655934A1 (en) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
PL2565204T3 (pl) * 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US20090246191A1 (en) * 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
SMT202000101T1 (it) * 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2011066221A1 (en) 2009-11-24 2011-06-03 International Aids Vaccine Initiative Immunogen prioritization for vaccine design
EP2572196A4 (en) 2010-05-18 2014-04-23 Christopher P Marshall ASSAY TO IDENTIFY ANTIGENES FOR THE ACTIVATION OF B-CELL RECEPTORS WITH NEUTRALIZING ANTIBODIES
US20130149336A1 (en) * 2011-10-27 2013-06-13 Brian L. Hjelle Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries
EP2804948B1 (en) 2012-01-20 2020-04-15 The Government of The Hong Kong Special Administrative Region of The People's Republic of China A novel paramyxovirus and uses thereof

Similar Documents

Publication Publication Date Title
Lanzavecchia et al. Antibody-guided vaccine design: identification of protective epitopes
Khurana et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets
JP2022023102A (ja) 新規多価ナノ粒子に基づくワクチン
Allen et al. Next generation methodology for updating HA vaccines against emerging human seasonal influenza A (H3N2) viruses
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
JP2015518819A5 (https=)
Fontana et al. Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
JP2020125323A5 (https=)
Tan et al. Recent advancements in combination subunit vaccine development
JP2014530010A5 (https=)
JP2013216685A5 (https=)
JP2017035093A5 (https=)
Wu et al. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus
JP2015524422A5 (https=)
HRP20241498T1 (hr) Antitijela usmjerena protiv t-staničnog imunoglobulina i mucin proteina 3 (tim-3)
JP2012501959A5 (https=)
Ellis et al. Antigen spacing on protein nanoparticles influences antibody responses to vaccination
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
Castro et al. Computational design of vaccine immunogens
JP2013523783A5 (https=)
Trucchi et al. Universal influenza virus vaccines: what needs to happen next?
Huang et al. N-linked glycans and K147 residue on hemagglutinin synergize to elicit broadly reactive H1N1 influenza virus antibodies
Brinkkemper et al. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
JP2022078254A5 (https=)